Drug
Iptacopan clinical trials
Also written LNP023.
- studies test it
- 27
- open now
- 11
- in phase 3
- 15
- first study started
- 2018
Keep track of what changes. Save the iptacopan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
- LNP023
- 20
Studies by the year they started
27 studies that test it; most in 2021 (8)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 4 |
| 2021 | 8 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 9
- Phase 3
- 15
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 2
Novartis Pharmaceuticals (25) · Bing Han (1) · First Affiliated Hospital of Zhejiang University (1)
Studies
Open first, then newest update. How each study uses iptacopan is read from its arms, and is right about nine times in ten.
Testing it · 27
- A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyRecruitingPhase 3Novartis PharmaceuticalsNCT04557462Written as LNP023
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANRecruitingPhase 3Novartis PharmaceuticalsNCT06994845Written as iptacopan
- Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic MicroangiopathyRecruitingNot applicableFirst Affiliated Hospital of Zhejiang UniversityNCT07347990Written as iptacopan
- Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGNRecruitingPhase 3Novartis PharmaceuticalsNCT03955445Written as LNP023
- Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH PatientsRecruitingPhase 3Novartis PharmaceuticalsNCT06934967Written as LNP023
- Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgANRecruitingPhase 2Novartis PharmaceuticalsNCT06797518Written as Iptacopan
- Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGNRecruitingPhase 3Novartis PharmaceuticalsNCT05755386Written as iptacopan
- Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.RecruitingPhase 3Novartis PharmaceuticalsNCT04817618Written as iptacopan
- Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUSRecruitingPhase 3Novartis PharmaceuticalsNCT05795140Written as Iptcaopan 200 mg
- Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)RecruitingPhase 3Novartis PharmaceuticalsNCT05935215Written as Iptacopan
- A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)Not yet recruitingNot applicableBing HanNCT06847607Written as Iptacopan
- Iptacopan in Patients With ANCA Associated VasculitisActive, not recruitingPhase 2Novartis PharmaceuticalsNCT06388941Written as Iptacopan
- A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationActive, not recruitingPhase 2Novartis PharmaceuticalsNCT05230537Written as Iptacopan (LNP023)
- A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.Active, not recruitingPhase 3Novartis PharmaceuticalsNCT06517758Written as Iptacopan
- Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04747613Written as Iptacopan
- Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor TherapyCompletedPhase 3Novartis PharmaceuticalsNCT04889430Written as Iptacopan
- Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.CompletedPhase 3Novartis PharmaceuticalsNCT05630001Written as Iptacopan
- Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy PatientsCompletedPhase 3Novartis PharmaceuticalsNCT04578834Written as LNP023
- Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological DisordersTerminatedPhase 2Novartis PharmaceuticalsNCT05086744Written as Iptacopan
- Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor TherapyCompletedPhase 3Novartis PharmaceuticalsNCT04820530Written as Iptacopan (LNP023)
See all 27 studies that test iptacopan →
Given in every arm · 1 — iptacopan is usual care beside what is tested
As the comparator · 1 — what is tested is compared with iptacopan
Codes
What other systems call iptacopan · ClinicalTrials.gg INT002086
- MeSH (NLM) C000730766iptacopanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8E05T07Z6WIPTACOPANConfirmed FDA, NLM, Wikidata
- Wikidata Q76803684iptacopanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C156691IptacopanOne source FDA
- DrugBank DB16200One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000730766 | iptacopan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8E05T07Z6W | IPTACOPAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q76803684 | iptacopan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C156691 | Iptacopan | One source FDA |
| DrugBank | DB16200 | — | One source Wikidata |
Also registered as iptacopan hydrochloride (UNII XW5CK7C6YH).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.